Table 1.

Patient characteristics of 11 melanoma patient treated with peptide-loaded dendritic cells

P	Sex	Age	AJCC	Primary tumour	Metastatic sites	Objective response	TTP (months)
1	f	40	M1c	Uvea melanoma	Liver	PD	3
2	m	52	M1c	NM, CLIV, 2.5 mm	Lung, kidney, soft tissue	PD	1
3	m	51	M0	NM, CL III, 0.42 mm
4	m	71	M1c	SSM, CL IV, 1.3 mm	Liver, lung, LN	PD	2
5	m	38	M1c	SSM, CL III, 0.9 mm	LN, kidney	PD	3
6	m	69	M1c	NM, CL IV, 6.0 mm	LN, liver	PD	3
7	m	72	M1c	NM, CLIV, 3.2 mm	Liver, LN, kidney	PD	2
8	m	72	M1c	Soft tissue melanoma	Soft tissue, skin	PD	1
9	m	40	M1a	SSM, CL III, 0.6 mm	LN, soft tissue	PD	4
10	m	52	M1c	Uvea melanoma	Liver, kidney, muscle, soft tissue	PD	3
11	w	36	M1c	SSM, CL III, 0.6 mm	Liver, spleen, LN, lung	PD	Immediately

Patient 3 was treated with DC vaccine in an adjuvant setting exhibiting no evidence of metastatic disease

Clark level CL, nodular melanoma NM, progressive disease PD, superficial spreading melanoma SSM, time to progression TTP